Angion Biomedica Corp. announced the first patient has been dosed in its Phase 2 trial of ANG-3070, an oral tyrosine kinase receptor inhibitor, in patients with primary proteinuric kidney diseases. ANG-3070 Program Update: Angion's lead product candidate is ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung.

Angion enrolled the first patient in its global dose-finding Phase 2 trial of ANG-3070 prior to the end of 2021. This is a randomized, double-blind, placebo-controlled trial intended to assess the safety and efficacy of ANG-3070 in adult patients with focal segmental glomerulosclerosis (FSGS) or immunoglobulin A nephropathy (IgAN), two types of primary proteinuric kidney diseases. The trial will enroll 100 patients equally among four treatment arms: 200mg ANG-3070 1x/day, 400mg ANG-3070 1x/day, 300mg ANG-3070 2x/day, and placebo with dosing for 12 weeks.

The primary endpoint in the study is the percentage change in 24-hour urinary protein excretion at week 12. Angion also expects to file an IND at the end of 2022 for a global Phase 2 trial of ANG-3070 in patients with idiopathic pulmonary fibrosis. Additional details as to patient population, trial size, and trial endpoints will be announced later this year.

ANG-3070 was featured in a recent R&D Day conducted by Angion. Angion and its partner Vifor Pharma continue to analyze the full data sets from the ANG-3777 clinical trial readouts reported in the fourth quarter of 2021. Angion expects to communicate its future plans for ANG-3777 in the first quarter of 2022.